Anavex Life Sciences

AVXL50

$7.44arrow_drop_down7.22%-$0.57

AVXL50

$7.44

arrow_drop_down7.22%-$0.57

Performance History

Key Stats
Open	$8.00
Prev. Close	$8.03
EPS	-0.47
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	7.42	8.10
52 Week Range	3.25	10.45

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.47

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Anavex Life Sciences (AVXL)

Anavex Life Sciences Corp (AVXL) is a biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of neurodegenerative diseases. The company's lead product candidate, ANAVEX®2-73, is being evaluated in multiple clinical studies for the treatment of Alzheimer's disease, Parkinson's disease, and Rett syndrome.

ANAVEX®2-73 is a small molecule that targets sigma-1 receptors, which play a key role in neuroprotection, neuroplasticity, and neuroregeneration. The drug has shown promising results in preclinical and early clinical studies, demonstrating its potential to improve cognitive function and reduce neuroinflammation in patients with neurodegenerative diseases.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Headquarters: New York
Employees: 38
Exchange: NASDAQ

Keep an eye on Anavex Life Sciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Anavex Life Sciences's (AVXL) price per share?

The current price per share for Anavex Life Sciences (AVXL) is $7.45. The stock has seen a price change of -$0.58 recently, indicating a -7.22% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Anavex Life Sciences (AVXL)?

For Anavex Life Sciences (AVXL), the 52-week high is $10.45, which is 40.36% from the current price. The 52-week low is $3.25, the current price is 129.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Anavex Life Sciences (AVXL) a growth stock?

Anavex Life Sciences (AVXL) has shown an average price growth of -6.65% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Anavex Life Sciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Anavex Life Sciences (AVXL) stock price performance year to date (YTD)?

As of the latest data, Anavex Life Sciences (AVXL) has a year-to-date price change of 23.16%. Over the past month, the stock has experienced a price change of 35.24%. Over the last three months, the change has been 18.55%. Over the past six months, the figure is 63.63%. Looking at a longer horizon, the five-year price change stands at 210.21%.

help

Is Anavex Life Sciences (AVXL) a profitable company?

Anavex Life Sciences (AVXL) has a net income of -$47.5M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$47.5M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Anavex Life Sciences (AVXL)?

Anavex Life Sciences (AVXL) has a market capitalization of $630.16M. The average daily trading volume is 7.66, indicating the stock's liquidity and investor engagement.